alxn1830
mAbexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started Aug 17, 2016 (NCT03643627)
Timeline
Indications
Mechanism of action
- IgG receptor FcRn large subunit p51INHIBITOR
FCGRT inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- synt001
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04982289 | Phase 2 | Jan 1, 2022 | Alexion |
| NCT04956276 | Phase 2 | Jan 1, 2022 | Alexion |
| NCT04730804 | Phase 1 | Mar 17, 2021 | Alexion, Syneos Health |
| NCT04256148 | Phase 2 | Feb 29, 2020 | Alexion |
| NCT05254613 | Phase 1 | Nov 12, 2019 | Alexion |
| NCT03075904 | Phase 1 | Apr 1, 2017 | Syntimmune, Inc. |
| NCT03075878 | Phase 1 | Apr 1, 2017 | Syntimmune, Inc. |
| NCT03643627 | Early Phase 1 (Phase 1) | Aug 17, 2016 | Syntimmune, Inc. |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Alexion | For profit | 5 | 5 | 2 | 2019 |
| Syntimmune, Inc. | For profit | 3 | 3 | 1 | 2016 |
| Syneos Health | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1